BBK welcomes Laura Ardigó as our guest contributor on the blog today. Laura is an independent clinical research consultant with broad experience working in multinational pharmaceutical companies and is currently the President at Fundación UnICA (United for Clinical Research in Argentina). She will be sharing her insights into the patient recruitment landscape of Latin America, discussing industry trends, assumptions, and how technologies and innovations can most effectively be used to support clinical research while keeping the patient first.
Last week on the blog we highlighted BBK’s RSG® Arrive service, which underscores our commitment to patient centricity by easing study visit travel complexities and in turn, expanding clinical research participation. We know that travel can be a hassle, but what if getting a patient to a site could mean the difference between receiving a potentially life-saving treatment or not? What makes a patient travel program such an integral part of the clinical trial landscape?
Imagine a program that takes the hassle out of patient travel within a clinical trial. When dealing with a condition of any sort, be it rare or otherwise, asking a patient to travel across state lines or even to another country, can be a source of anxiety and for many, a financial hardship. Many rare diseases especially, affect newborns who require a parent or guardian to handle travel logistics and accompany the patient. In many instances, travel can affect an entire family not once, but for multiple site visits throughout the course of a study. If not the patients themselves, many parents, guardians or caregivers determine that the complexity involved in getting to a site might outweigh the benefits of participation in a clinical trial. But what if the burden associated with travel could be eliminated?
Topics: Patient Travel
This past July 15th, the FDA tilted its regulator hat and announced the release of a new Draft Guidance, Informed Consent Information Sheet, to help clinical investigators and sponsors involved in clinical trials obtain informed consent from subjects. The new Draft Guidance provides important updates to the FDA’s informed consent policies and covers the specific responsibilities of IRBs, clinical investigators, and sponsors regarding informed consent.
Topics: Patient Centricity
There wasn't a dry eye in the audience last night when the acclaimed ESPN veteran Stuart Scott accepted his Jimmy V Perseverance Award at the 2014 ESPYS last night. The longtime SportsCenter personality opened up about his seven-year battle with appendiceal cancer – in which he has endured fifty-eight chemotherapy infusions, three abdomen surgeries and countless treatments as he continues to fight the disease.
Topics: Patient Advocacy
DIA 2014 50th Annual Meeting, SAN DIEGO, Calif. and BOSTON, Mass., June 17, 2014 --BBK Worldwide, a leading clinical trial marketing firm, and CROèe, the first consulting Japanese CRO specializing in patient recruitment, today announced the creation of a jointly-owned US-based company, BBK + CROèe. Collaborators since 2010, the new partners formed the entity to provide the cultural and marketing expertise necessary to engage the Japanese pharmaceutical industry and, in turn, to support global pharma in its quest for drug approvals in Japan, the second largest pharmaceutical marketplace in the world next to the US.
Topics: BBK Worldwide
It's not new to say that parents want the best for their kids – from education, opportunities, healthcare, and beyond. The same notion holds true in pediatric clinical studies.